ABACAVIR SULFATE
Proposal for revision of The International Pharmacopoeia
(August 2012)

Draft for comment

This document was provided by a quality control expert. Should you have any comments thereon, please send these to Dr Herbert Schmidt, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, World Health Organization, 1211 Geneva 27, Switzerland; fax: (+41 22) 791 4730 or e-mail: schmidt.h.who.int with a copy to gaspardm.who.int by 20 September 2012.

In order to speed up the process for receiving draft monographs and for sending comments, please let us have your e-mail address (to bonnyw.who.int) and we will add it to our electronic mailing list. Please specify if you wish to receive monographs.

© World Health Organization 2012
All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted; reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned staff and member organizations) without the permission of the World Health Organization. The draft should not be displayed on any web site.

Please send any request for permission to:
Dr Sabine Kopp, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, Department of Essential Medicines and Health Products, World Health Organization, CH-1211 Geneva 27, Switzerland. Fax: (41-22) 791 4730; e-mail: kopp.s.who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.
### SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/12.487

*Draft proposal for revision of a published monograph in The International Pharmacopoeia*

**ABACAVIR SULFATE**

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussion of preliminary draft revision at consultation on specifications for medicines and quality control laboratory issues</td>
<td>29-31 May 2012</td>
</tr>
<tr>
<td>Draft sent out for comments following discussion at consultation on specifications for medicines and quality control laboratory issues</td>
<td>August 2012</td>
</tr>
<tr>
<td>Collation of comments received</td>
<td>August-September 2012</td>
</tr>
<tr>
<td>Discussion at forty-seventh meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations</td>
<td>9-12 October 2012</td>
</tr>
<tr>
<td>Further follow-up action as required</td>
<td></td>
</tr>
</tbody>
</table>
ABACAVIR SULFATE

[Note from the secretariat:

It is proposed to revise the solubility of Abacavir sulfate from “freely soluble in water” to “soluble in water”.]

Abacaviri sulfas
Abacavir sulfate

\[
\text{(C}_{14}\text{H}_{18}\text{N}_6\text{O})_2\text{H}_2\text{SO}_4
\]

Relative molecular mass. 670.8

Chemical name. Abacavir sulfate is \((1\text{S},4\text{R})\)-4-[2-Amino-6(cyclopropylamino)-9\(H\)-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate; CAS Reg. No. 188062-50-2.

Description. White to almost white powder.

Solubility. Freely soluble in water.

Category. Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor).

Storage. Abacavir sulfate should be kept in a well-closed container.

Requirements

Definition. Abacavir sulfate contains not less than 99.0% and not more than 101.0% of \((\text{C}_{14}\text{H}_{18}\text{N}_6\text{O})_2\text{H}_2\text{SO}_4\) calculated with reference to the anhydrous substance.

Manufacture. The production method is validated to demonstrate that the substance, if tested, would comply with a limit of not more than 0.5% for \((1\text{R}, 4\text{S})\)-abacavir enantiomer using a suitable chiral chromatographic method.
Identity tests

• Either tests A, B, D and E or tests C, D and E may be applied

A. Carry out test A.1 or, where UV detection is not available, test A.2.

A.1 Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R6 as the coating substance and a mixture of 8 volumes of dichloromethane R and 2 volumes of 2-propanol R as the mobile phase. Apply separately to the plate 5 µl of each of 2 solutions in methanol containing (A) 5 mg of the test substance per ml and (B) 5 mg of abacavir sulfate RS per ml. After removing the plate from the chromatographic chamber, allow it to dry exhaustively in air or in a current of cool air. Examine the chromatogram in ultraviolet light (254 nm).

The principal spot obtained with solution A corresponds in position, appearance and intensity to that obtained with solution B.

A.2 Carry out the test as described under 1.14.1 Thin-layer chromatography, using the conditions described above under test A.1 but using silica gel R5 as the coating substance. Spray with vanillin/sulfuric acid TS1. Heat the plate for a few minutes at 120 °C. Examine the chromatogram in daylight.

The principal spot obtained with solution A corresponds in position, appearance and intensity to that obtained with solution B.

B. The absorption spectrum (1.6) of a 15 µg per ml solution, when observed between 210 and 300 nm, exhibits a maximum at about 291 nm; the specific absorbance (Å) is between 399 and 441 nm.

C. Carry out the examination as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from abacavir sulfate RS or with the reference spectrum of abacavir sulfate.

D. Determine the specific optical rotation (1.4) using a 10 mg/ml solution and calculate with reference to the anhydrous substance; [α]D25°C = -53° to -57°.

E. A 10 mg/ml solution yields reaction A described under 2.1 General identification tests, as characteristic of sulfates.

Heavy metals. Use 1.0 g for the preparation of the test solution as described under 2.2.3 Limit test for heavy metals, Procedure 1; determine the heavy metal content according to Method A; not more than 20 µg/g.

Sulfated ash (2.3). Not more than 2.0 mg/g.

Water. Determine as described under 2.8 Determination of water by the Karl Fischer method, Method A. Use 1.0 g of the test substance. The water content is not more than 5 mg/g.

Related substances. Carry out the test as described under 1.14.4 High-performance liquid chromatography, using a stainless steel column (15 cm x 4.6 mm), packed with octadecylsilyl silica gel for chromatography (5 µm).
The mobile phases for gradient elution consist of a mixture of Mobile phase A and Mobile phase B, using the following conditions:

Mobile phase A: 0.05% solution of trifluoroacetic acid R.

Mobile phase B: 85 volumes of methanol R and 15 volumes of water.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Mobile phase A (% v/v)</th>
<th>Mobile phase B (% v/v)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 20</td>
<td>95 to 70</td>
<td>5 to 30</td>
<td>Linear gradient</td>
</tr>
<tr>
<td>20 - 35</td>
<td>70 to 10</td>
<td>30 to 90</td>
<td>Linear gradient</td>
</tr>
<tr>
<td>35 - 40</td>
<td>10 to 95</td>
<td>90 to 5</td>
<td>Return to initial composition</td>
</tr>
<tr>
<td>40 - 45</td>
<td>95</td>
<td>5</td>
<td>Re-equilibration</td>
</tr>
</tbody>
</table>

Operate with a flow rate of 0.8 ml per minute and the column oven temperature at 30 °C. As a detector use an ultraviolet spectrophotometer set at a wavelength of about 254 nm.

Prepare the following solutions in the dissolution solvent prepared by diluting 1 ml of phosphoric acid (~1440g/l) TS in 1 litre of water.

For solution (1) dissolve 10 mg of the test substance in the dissolution solvent and dilute to 50.0 ml with the same solvent. For solution (2) dilute 5.0 ml of solution (1) to 50.0 ml with the dissolution solvent. Then dilute 5.0 ml of this solution to 50.0 ml with the same solvent.

For solution (3) dissolve 5 mg of abacavir sulfate for system suitability RS (containing abacavir sulfate and impurities B to F) in the dissolution solvent and dilute to 25 ml with the same solvent.

Inject separately 20μl each of solutions (1), (2) and (3) and of the dissolution solvent in the chromatographic system. Examine the blank chromatogram for any extraneous peaks and disregard the corresponding peaks observed in the chromatogram obtained with solution (1).

In the chromatogram obtained with solution (3), the impurity peaks are eluted at the following relative retention with reference to abacavir (retention time about 19 minutes): impurity C about 0.6; impurity D about 1.05; impurity E about 1.10; impurity B about 1.3; impurity F about 1.7. The test is not valid unless the resolution between the peaks corresponding to abacavir and impurity D is at least 1.5.

In the chromatogram obtained with solution (1) the area of any individual peak corresponding to impurity C, D, E, B, or F is not greater than 0.3 times the area of the principal peak obtained with solution (2) (0.3%). The area of any other impurity peak is not greater than 0.1 times the area of the principal peak obtained with solution (2) (0.1%). The sum of the areas of all peaks, other than the principal peak, is not greater than the area of the principal peak obtained with solution (2) (1%). Disregard any peak with an area less than 0.05 times the area of the principal peak obtained with solution (2) (0.05%).

Assay. Dissolve about 0.300 g, accurately weighed, in 50 ml of water and titrate with sodium hydroxide (0.1 mol/l) VS, determining the end-point potentiometrically.

Each ml of sodium hydroxide (0.1 mol/l) is equivalent to 33.54 mg of \((C_{14}H_{18}N_6O_2)_2H_2SO_4\).
Impurities

A. (1R, 4S)-abacavir sulfate enantiomer (see under Manufacture),

B. N⁶-cyclopropyl-9-((1R,4S)-4{[(2,5-diamino-6-chloro-4-pyrimidinyl)oxy]methyl}-2-cyclopenten-1-yl)-9H-purine-2,6-diamine,

C. [(1S,4R)-4-(2,6-diamino-9H-purin-9-yl)-2-cyclopenten-1-yl]methanol,
D. \{(1R,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopenten-1-yl\}methanol,

\[\text{Diagram} \]

E. \{(1R,4S)-3-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl] cyclopentyl\}methanol,

\[\text{Diagram} \]


***